Literature DB >> 35362854

Clazosentan: First Approval.

Arnold Lee1.   

Abstract

Clazosentan (PIVLAZ™) is a small molecule, endothelin (ET) A receptor-selective antagonist being developed by Idorsia Pharmaceuticals. ETA receptor inhibition by clazosentan decreases ET-related cerebral vasospasm, which may occur after an aneurysmal subarachnoid haemorrhage. Clazosentan has been approved in Japan for use in the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischaemic symptoms after aneurysmal subarachnoid haemorrhage, following the results from the JapicCTI163369 and JapicCTI163368 phase III trials. This article summarises the milestones in the development of clazosentan leading to this first approval in this indication.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35362854     DOI： 10.1007/s40265-022-01708-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  11 in total

1.  Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.

Authors:  R Loch Macdonald; Randall T Higashida; Emanuela Keller; Stephan A Mayer; Andy Molyneux; Andreas Raabe; Peter Vajkoczy; Isabel Wanke; Doris Bach; Aline Frey; Pegah Nowbakht; Sébastien Roux; Neal Kassell
Journal:  Stroke       Date:  2012-03-08       Impact factor: 7.914

2.  Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).

Authors:  R Loch Macdonald; Randall T Higashida; Emanuela Keller; Stephan A Mayer; Andy Molyneux; Andreas Raabe; Peter Vajkoczy; Isabel Wanke; Doris Bach; Aline Frey; Angelina Marr; Sébastien Roux; Neal Kassell
Journal:  Acta Neurochir Suppl       Date:  2013

3.  Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.

Authors:  Miki Fujimura; Jin-Yang Joo; Jong-Soo Kim; Motonori Hatta; Yoshinari Yokoyama; Teiji Tominaga
Journal:  Cerebrovasc Dis       Date:  2017-05-03       Impact factor: 2.762

4.  Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.

Authors:  Gang Chen; Asma Tariq; Jinglu Ai; Mohammed Sabri; Hyo-Jin Jeon; Elaine J Y Tang; Katarina Lakovic; Hoyee Wan; R Loch Macdonald
Journal:  Brain Res       Date:  2011-04-03       Impact factor: 3.252

5.  Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm.

Authors:  S Roux; V Breu; T Giller; W Neidhart; H Ramuz; P Coassolo; J P Clozel; M Clozel
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

6.  Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelin(B) receptor-mediated relaxation.

Authors:  Hartmut Vatter; Michael Zimmermann; Veronika Tesanovic; Andreas Raabe; Volker Seifert; Lothar Schilling
Journal:  J Neurosurg       Date:  2005-06       Impact factor: 5.115

7.  Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction.

Authors:  Hartmut Vatter; Michael Zimmermann; Veronika Tesanovic; Andreas Raabe; Lothar Schilling; Volker Seifert
Journal:  J Neurosurg       Date:  2005-06       Impact factor: 5.115

8.  Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.

Authors:  Randall T Higashida; Nicolas Bruder; Rajiv Gupta; Raphael Guzman; Abdel Hmissi; Angelina Marr; Stephan A Mayer; Sébastien Roux; Stefan Weidauer; E François Aldrich
Journal:  World Neurosurg       Date:  2019-05-02       Impact factor: 2.104

9.  Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.

Authors:  Pierre-Eric Juif; Jasper Dingemanse; Christine Voors-Pette; Mike Ufer
Journal:  AAPS J       Date:  2020-08-03       Impact factor: 4.009

10.  Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.

Authors:  R Loch Macdonald; Neal F Kassell; Stephan Mayer; Daniel Ruefenacht; Peter Schmiedek; Stephan Weidauer; Aline Frey; Sebastien Roux; Alberto Pasqualin
Journal:  Stroke       Date:  2008-08-07       Impact factor: 7.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.